Re-expression of elafin in 21MT2 breast carcinomas by phorbol 12- myristate 13-acetate is mediated by the Ap1 site in the elafin promoter

Cancer Research

Volumn 57, Issue 20, 1997, Pages 4631-4636

  Zhang, Ming ^a,b   Magit, David ^a   Pardee, Arthur B ^a   Sager, Ruth ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHORBOL 13 ACETATE 12 MYRISTATE;

ARTICLE; BASEMENT MEMBRANE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER INVASION; CELL PROTECTION; ENZYME ACTIVE SITE; ENZYME INHIBITION; GENE DELETION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MUTAGENESIS; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

BINDING SITES; BREAST; BREAST NEOPLASMS; CELLS, CULTURED; CHLORAMPHENICOL O-ACETYLTRANSFERASE; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; PROMOTER REGIONS (GENETICS); PROTEIN BIOSYNTHESIS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; RECOMBINANT FUSION PROTEINS; SERINE PROTEINASE INHIBITORS; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030882327     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Magnatti, P., and Rifkin, D. B. Biology and biochemistry of proleinases in tumor invasion. Physiol. Rev., 73: 161-185, 1991.
2. Stetler-Stevenson, W. G., Aznavoorian, S., and Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell. Biol., 9: 541-573, 1994.
3. DeClerck, Y. A., and Imren, S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur. J. Cancer, 30A: 2170-2180, 1994.
4. Sumiyoshi, K., Baba, S., Sakaguchi, S., Urano, T., Takada, Y., and Takada, A. Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. Thromb. Res., 63: 59-71, 1991.
5. Cajot, J-F., Bamat, J., Bergonzelli, G. E., Kruithof, E. K. O., Medcalf, R. L., Testuz, J., and Sordat, B. Plasminogen activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc. Natl. Acad. Sci. USA, 87: 6939-6943, 1990.
6. Buck, M. R., Karustis, D. G., Day, N. A., Honn, K. V., and Sloan, B. F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem. J., 282: 273-278, 1992.
7. Sloane, B. F., Moin, K., and Lah, T. T. In: T. G. and T. P. Pretlow (eds.), Aspects of Biochemistry and Molecular Biology of Tumors, pp. 411-466. New York: Academic Press, 1994.
8. Bassett, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, O. L., Chenard, M. P., Rio, M. C., and Chambon, P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (Lond.), 348: 699-704, 1990.
9. Gutman, A., and Wasylyk, B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J., 9: 2241-2246, 1990.
10. Buttice, G., and Kurkinen, M. A polyomavirus enhancer A-binding protein-3 site and ETS-2 protein have a major role in the 12-O-tetradecanoylphorbol-13-acetate response of the human stromelysin gene. J. Biol. Chem., 268: 7169-7204, 1993.
11. Kaya, M., Yoshida, K., Higashino, F., Mitaka, T., Ishii, S., and Fujinaga, K. A single ETS-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene, 12: 221-227, 1996.
12. Boccia, L. M., Lillicrap, D., Newcombe, K., and Mueller, C. R. Binding of the ETS factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transcription. Mol. Cell. Biol., 16: 1929-1935, 1996.
13. Nerlov, C., Rorth, P., Blasi, F., and Johnsen, M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene, 6: 1583-1592, 1991.
14. Nerlov, C., Cesare, D., Pergola, F., Caracciolo, A., Blasi, F., Johnsen, M., and Verde, P. A regulatory element that mediates co-operation between a PEA3-AP1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J., 11: 4573-4582, 1992.
15. Wargnier, A., Legros-Maida, S., Bosselut, R., Bourge, J. F., Lafaurie, C., Ghysdael, C. J., Saportes, M., and Paul, P. Identification of human granzyme B promoter regulatory elements interacting with activated T-cell-specific proteins: implication of Ikaros and CBF binding sites in promoter activation. Proc. Natl. Acad. Sci. USA, 92: 6930-6934, 1995.
16. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
17. Duffy, M., Reilly, D. C., O'Sullivan, C., O'Higgins, N., Fennelly, J., and Andreasen, P. A. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50: 6827-6829, 1990.
18. Sappino, A. P., Busso, N., Belin, D., and Vassali, J. D. Increase of urokinase type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res., 47: 4043-4046, 1987.
19. Nakajima, M., Lotan, D., Baig, M., Carralero, R. M., Wood, W. R., Hendrix, M. J. C., and Lotan, R. Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res., 49: 1698-1706, 1989.
20. Zou, Z., Anisowicz, A., Hendrix, M. J. C., Thor, A., Neveu, M., Sheng, S., Rafidi, K., Seftor, E., and Sager, R. Identification of a novel serpin with tumor suppressing activity in human mammary epithelial cells. Science (Washington DC), 263: 526-529, 1994.
21. Sotiropoulou, G., Anisowicz, A., and Sager, R. Identification, cloning and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J. Biol. Chem., 272: 903-910, 1997.
22. Zhang, M., Zou, Z., Maass, N., and Sager, R. Differential expression of elafin in normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. Cancer Res., 55: 2537-2541 1995.
23. Weidow, O., Schroder, J. M., Gregory, S. H., Young, J. A., and Christophers, E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization and complete amino acid sequence. J. Biol. Chem., 265: 14791-14795, 1990.
24. Alkemade, H. A. C., Molhuizen, H. O. F., van Vlijmen-Willems, I. M. J. J., van Healst, U. J. G. M., and Schalwijk, J. Differential expression of Skalp/Elafin in human epidermal tumors. Am. J. Pathol., 143: 1679-1687, 1993.
25. Hennighausen, L. G., and Sippel, A. E. Mouse whey acidic protein is a novel member of the family of "four-disulfide core" proteins. Nucleic Acids Res., 10: 2677-2684, 1982.
26. Molhuizen, H. O., Alkemade, H. A. C., Zeeuwen, P. L. J. M., de Jongh, G. J., Wieringa, B., and Schalkwijk, J. SKALP/elafin. An elastase inhibitor from cultured human keratinocytes. J. Biol. Chem., 268: 12028-12032, 1993.
27. Nara, K., Ito, S., Suzuki, Y., Ghoneim, M. A., Tachibana, S., and Hirose, S. Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin." J. Biochem., 115: 441-448, 1994.
28. Saheki, T., Ito, F., Hagiwara, H., Saito, Y., Kuroki, J., Tachibana, S., and Hirose, S. Primary structure of the human elafin precursor preproelafin deduced from nucleotide sequence of its gene and the presence of unique repetitive sequences in the prosegment. Biochem. Biophys. Res. Commun., 185: 240-245, 1992.
29. Wiedow, O., Lüdemann, J., and Utecht, B., Elafin is a potent inhibitor of proteinase 3. Biochem. Biophys. Res. Commun., 174: 6-10, 1991.
30. Band, V., and Sager, R. Distinctive traits of normal and tumor derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proc. Natl. Acad. Sci. USA, 86: 1249-1253, 1989.
31. Swisshelm, K., Ryan, K., Lee, X., Tsou, H. C., Peacocke, M., and Sager, R. Down-regulation of retinoic acid receptor β in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ., 5: 133-141, 1994.
32. Laborda, J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res., 19: 3998, 1991.
33. Gorman, C. M., Moffat, L. F., and Howard, B. H. Recombinant genomes which express chloramphenicol acetyl transferase in mammalian cells. Mol. Cell. Biol., 2: 1044-1057, 1982.
34. Dignam, J., Lebovitz, R., and Roeder, R. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11: 1475-1489, 1983.
35. Trilivas, I., McDonough, P. M., and Brown, J. H. Dissociation of protein kinase C redistribution from the phosphorylation of its substrates. J. Biol. Chem., 266: 8431-8438, 1991.
36. Trejo, J., Massamiri, T., Deng, T., Dewji, N. N., Bayney, R. M., and Brown, J. H. A direct role for protein kinase C and the transcription factor Jun/AP-1 in the regulation of the Alzheimer's β-amyloid precursor protein gene. J. Biol. Chem., 269: 21682-21690, 1994.
37. Ueda, E., Ohno, S., Kuroki, T., Livneh, E., Yamada, K., Yamanishi, K., and Yasuno, H. The η isoform of protein kinase C mediates transcriptional activation of the human transglutaminase 1 gene. J. Biol. Chem., 271: 9790-9794, 1996.
38. Curren, T., and Franza, B. R. Fos and Jun: the AP-1 connection. Cell, 55: 395-397, 1988.
39. Boyle, W. J., Meek, J., Smeal, T., Hunter, T., and Karin, M. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell. 54: 541-552, 1988.
40. Angel, P., Imagawa, M., Chui, R., Stein, B., Imbra, R. J., Rahmsdorf, H. J., Jonat, C., Herrlich, P., and Karin, M. Phorbol ester inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell, 49: 729-739, 1987.
41. Zhang, M., Maass, N., Magit, D., and Sager, R. Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor suppressing gene maspin. Cell Growth Differ., 8: 179-186, 1997.
42. Crawford, H. C., and Matrisian, L. M. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein, 49: 20-37, 1996.
43. Gaire, M., Magbanua, Z., McDonnell, S., McNeil, L., Lovett, D. H., and Matrisian, L. M. Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J. Biol. Chem., 269: 2032-2040, 1994.
44. Trimble, M., Xin, J., Guy, C. T., Muller, W., and Hassell, J. PEA3 is overexpressed in mouse mammary adenocarcinomas. Oncogene, 8: 3037-3042, 1993.
45. Domann, F. E., Levy, J. P., Finch, J. S., and Bowden, G. T. Constitutive AP-1 DNA binding and transactivating ability of malignant but not benign mouse epidermal cells. Mol. Carcinog., 9: 61-66, 1994.
46. Dong, Z., Birrer, M. J., Watts, R. G., Matrisian, L. M., and Colburn, N. H. Blocking of tumor promoter-induced AP-1 activity through induction of Fra expression. Proc. Natl. Acad. Sci. USA, 94: 952-955, 1997.
47. Sager, R., Expression genetics in cancer: shifting the focus from DNA to RNA. Proc. Natl. Acad. Sci. USA, 94: 952-955, 1997.
48. Sutherland, J. A., Cook, A., Bannister, A. J., and Kouzarides, T. Conserved motifs in Fos and Jun define a new class of activation domain. Genes Dev., 6: 1810-1819, 1992.
49. Adler, V., Pincus, M. R., Brandt-Rauf, P. W., and Ronai, Z. Complexes of p21RAS with JUN N-terminal kinase and JUN proteins. Proc. Natl. Acad. Sci. USA, 92: 10585-10589, 1995.
50. Binetruy, B., Smeal, T., and Karin, M. Ha-ras augments c-Jun activity and stimulates phosphorylation of its activation domain. Nature (Lond.), 351: 122-127, 1991.
51. Abate, C., Baker, S. J., Lees-Miller, S. P., Anderson, C. W., Marshak, D. R., and Curran, T. Dimerization and DNA binding alter phosphorylation of Fos and Jun. Proc. Natl. Acad. Sci. USA, 90: 6766-6770, 1993.